LUNGevityKristin Posted May 14, 2020 Share Posted May 14, 2020 Press Release: GENENTECH TO PRESENT FIRST CLINICAL DATA ON NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY TIRAGOLUMAB AT ASCO PHASE II CITYSCAPE TRIAL SHOWS PROMISING RESULTS ADDING TIRAGOLUMAB TO TECENTRIQ IN PEOPLE WITH PD-L1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCERFULL RESULTS WILL BE PRESENTED IN AN ORAL ABSTRACT SESSION AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM ORGANIZED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) https://www.gene.com/media/press-releases/14852/2020-05-13/genentech-to-present-first-clinical-data Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.